Status:

COMPLETED

Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers

Lead Sponsor:

NanoSHIFT LLC

Conditions:

Diabetic Foot Ulcer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This study is a double-blind, one center, two-arm study with a two (2) week Run-In, evaluating the efficacy of a once-daily administration of NanoDOX™ Hydrogel topically applied to diabetic ulcers in ...

Detailed Description

Study of NanoDOX vs placebo on diabetic ulcers of the lower leg/foot.

Eligibility Criteria

Inclusion

  • Have a documented history of type I or type II diabetes mellitus as defined by the American Diabetes Association
  • Women of childbearing potential must have a negative urine pregnancy test at screening and at baseline, and:
  • • Agree to use a double-barrier method of contraception during their participation in this study;
  • condoms (with spermicide) and hormonal contraceptives OR
  • condoms (with spermicide) and intrauterine device OR
  • intrauterine device and hormonal contraceptives OR
  • Abstains from sexual intercourse during their participation in this study OR
  • Is with a same-sex partner and does not participate in bisexual activities where there is a risk of becoming pregnant
  • Have an ulcer on the lower extremity (distal to a line connecting the medial and lateral malleoli) that has been present for at least 3 weeks and that is 1.2 cm2 to 4.0 cm2 at initial screening
  • Be able to apply study drug to their ulcer, or have a caregiver do it
  • Adequate blood flow to target ulcer extremity as measured by transcutaneous oxygen tension (TcpO2) of \>30mmHg
  • Target ulcer is Grade I according to the Wagner Grading Scale
  • Quantitative bacterial count of of \< 1.0 x 1.0E5 per gram of tissue for non-infected ulcers
  • Quantitative bacterial count of ≥ 1.0 x 1.0E5 per gram of tissue for infected ulcers

Exclusion

  • Be a pregnant or lactating woman or a female of childbearing potential who is not practicing acceptable form of birth control.
  • Allergy to tetracycline, minocycline, demeclocycline, or any other known tetracycline derivative
  • Have more than three chronic ulcers present at baseline
  • Have undergone treatment with system corticosteroid or immunosuppressive therapy in the past 2 months
  • Have connective tissue disease
  • Currently be going through kidney dialysis for renal failure
  • Have undergone treatment with doxycycline, Procuren®, or Regranex® within the last 30 days
  • Have participated in another clinical research trial within the last 30 days
  • Have a known history of osteomyelitis affecting to the area where the target ulcer is present
  • Have any other concomitant condition which, in the opinion of the investigator, would make the subject unsuitable for the study.
  • Subject has ulcers resulting from any cause other than diabetes (electrical burn, arterial insufficiency, chemical or radiation insult)

Key Trial Info

Start Date :

January 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2010

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT00764361

Start Date

January 1 2009

End Date

August 1 2010

Last Update

April 7 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

North Florida / South Georgia Veterans Administration Hospital

Gainesville, Florida, United States, 32608